I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Periodontitis is an immunoinflammatory disease of supporting tissues of the teeth, caused by specific microorganisms, resulting in the progressive destruction of periodontal ligament and alveolar bone with pocket formation.\[[@ref1]\] Regeneration of lost attachment apparatus is the ultimate goal of any periodontal therapy. Although various bone grafts have been used in the past two decades, it resulted in the formation of long junctional epithelium.

To achieve greater predictability with regenerative therapy requires the introduction of a pharmacological agent that not only hampers tissue destruction but also enhances the regenerative capabilities of periodontal tissues. There was a daunting need for an agent that could provide with the dual benefit of inhibiting bone resorption and stimulating the bone formation, thus leading to the regeneration of periodontium. Then, "statins" came into the field of periodontics. Statins, such as the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR) inhibitors, are well-established cholesterol-lowering drugs.\[[@ref2]\] They modify the inflammatory cascades through pleiotropic actions at multiple levels. Their pleiotropic actions include anti-inflammatory and antioxidant actions, immunomodulation, and increased angiogenesis and bone formation. Simvastatin administered in the prodrug form, which is much more lipophilic than other statins, can effectively cross cellular membrane barriers by passive diffusion. The low cost and impressive long-term safety profile of this compound makes it a suitable agent in periodontal therapy.\[[@ref3]\]

The use of simvastatin to promote new bone formation in periodontitis patients depends on its concentration and appropriate delivery system. There are various forms available of which collagen is biocompatible, is bioresorbable, and adapts easily to the shape of defects. The ability of collagen membrane to stimulate adhesion, chemotaxis, and physiological degradation of progenitor cells, together with the possibility of its own degradation, makes it an ideal material for building the membrane.\[[@ref4]\]

Receptor activator of nuclear factor kappa-B ligand (RANKL) interacts with its corresponding receptor RANK on mononucleated osteoclast precursors and induces their activation to multinuclear bone resorbing osteoclasts.\[[@ref5]\] The effects of RANKL are blocked by its soluble decoy receptor osteoprotegerin (OPG), thus inhibiting osteoclast differentiation, activation, and survival.\[[@ref6]\]

Gingival crevicular fluid (GCF) is regarded as a window for noninvasive analysis of periodontal conditions, including markers of connective tissue and bone destruction. Recent clinical studies have confirmed that both RANKL and OPG can be detected in human GCF, and indicate that RANKL is elevated, whereas OPG is decreased in periodontitis.\[[@ref7][@ref8]\]

To date, there is no information regarding the RANKL and OPG levels after placement of collagen membrane with simvastatin in intrabony defects. Thus, the aim of this study was to investigate RANKL and OPG levels in GCF after placement of collagen membrane with simvastatin in intrabony defects of chronic periodontitis.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Study population and clinical examination {#sec2-1}
-----------------------------------------

A total of 60 subjects were included in this study. Subjects were selected from the outpatients in Department of Periodontics, JKK Nattraja Dental College and Hospitals, Komarapalayam, Tamil Nadu, India. The protocol was reviewed and approved by institutional ethical board. The study-related procedures were explained to the patients before they sign an informed consent form. A split-mouth design was planned, in which two contralateral sites with \>5 mm probing pocket depth and radiographic evidence of bone loss at baseline were chosen. Probing pocket depth was standardized with acrylic stent in all the selected areas.

Criteria for inclusion were individuals with age limit of 20--50 years of both gender; probing depth of \>5 mm as assessed by William's graduated probe, and patients with minimum of two contralateral intrabony defects. Criteria for exclusion were individuals with known systemic diseases, short- and long-term therapies, previous periodontal therapy, known drug allergy, teeth with traumatic occlusion, smokers, pregnancy, and lactating women. Subjects were classified according to the treatment plan as Group I and Group II. Group I included patients with intrabony defects treated with collagen membrane. Group II included patients with intrabony defects treated with simvastatin of 1.5 mg concentration incorporated into the collagen membrane.

Collection of Gingival crevicular fluid {#sec2-2}
---------------------------------------

The sites were isolated by cotton rolls and gently air-dried to remove saliva. Any supragingival plaque was removed from the sites before GCF collection with a sterile curette. A 1--5 μL sterile glass microcapillary pipette was placed at the opening of the periodontal pocket and left for 30 s to draw 2 μL GCF into the microcapillary tube. The sample was discarded if blood was detected within the microcapillary tube. Each GCF sample was immediately placed into a sterile, labeled Eppendorf tube and placed on ice, and then transported to the laboratory for processing. GCF samples were collected at baseline and 21 days. All the samples were immediately stored at 80°C. One examiner made all clinical measurements and collected all microbial and GCF samples.

Analysis of RANKL and OPG in GCF {#sec2-3}
--------------------------------

The amount of RANKL and OPG in the samples was determined by commercial ELISA kits (Biomedica Medizinprodukte). Briefly, 100 μL standard and GCF samples were added to the wells in duplicate; 100 μL detection antibody was added to all wells, except negative control, mixed gently, strips covered with plastic film, and incubated for 16--24 h at 4°C. Plates were incubated with 200 μL conjugate for 50 min at room temperature (18°C--26°C). The plates were then washed five times and 200 μL of substrate was added and incubated for 30min at room temperature (18°C--26°C) in the dark. The reaction was stopped by the addition of 50 μL stop solution and color was measured in an automated microplate spectrophotometer.

Statistical analysis {#sec2-4}
--------------------

The data were compiled in a Microsoft excel sheet and transferred to SPSS software, version 20. Descriptive statistics and inferential statistics were applied. The results obtained were analyzed statistically and comparisons were made within each group using Student's paired distribution "*t*-test." In all tests, *P* \> 0.05 was considered nonsignificant (NS), *P* \< 0.05 as significant, and *P* \< 0.001 as highly significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Analysis of RANKL and OPG levels in GCF {#sec2-5}
---------------------------------------

RANKL levels were significantly elevated in patients having intrabony defects treated with collagen membrane \[123.7 ± 0.24 (pg/mL)\] when compared with patients having intrabony defects treated with collagen membrane along with simvastatin \[58.0 ± 0.21 (pg/mL)\]. When comparing both the groups, Group II had more statistically significant (*P* \< 0.001\*\*) decrease in the levels of RANKL than Group I, as shown in [Table 1](#T1){ref-type="table"} and [Graph 1](#F1){ref-type="fig"}.

###### 

Comparison between Group I and Group II based on RANKL (pg/mL) and OPG (pg/mL) using Student's paired t-test

                       Groups   *n*     Mean    Standard deviation   *t*     *df*   *P* value   Mean difference   Standard error difference   95% Confidence interval of the difference   
  -------------------- -------- ------- ------- -------------------- ------- ------ ----------- ----------------- --------------------------- ------------------------------------------- --------
  **RANKL (pg/mL)-**   I        60      123.7   10.22                25.21   58     0.001\*\*   −65.7             2.606                       −70.91                                      −60.48
  II                   60       58      9.96                                                                                                                                              
  **OPG (pg/mL)**      I        60      60      7.42                 27.8    58     0.001\*\*   60.2              2.165                       55.86                                       64.53
  II                   60       120.2   9.24                                                                                                                                              

Group I = without simvastatin; Group II = with simvastatin

\*\*Highly significant (*P* \< 0.001)

![Comparison between Group I and Group II based on RANKL (pg/mL) and OPG (pg/mL).](JPBS-11-301-g001){#F1}

In contrast to RANKL, the OPG levels were significantly decreased in patients having intrabony defects treated with collagen membrane \[60.0 ± 0.64 (pg/mL)\] when compared with patients having intrabony defects treated with collagen membrane along with simvastatin \[120.20 ± 0.61 (pg/mL)\]. When comparing both the groups, Group II had more statistically significant (*P* \< 0.001\*\*) increase in the levels of OPG than Group I, as shown in [Table 1](#T1){ref-type="table"} and [Graph 1](#F1){ref-type="fig"}.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The regulation of bone resorption is orchestrated by RANKL and its cognate inhibitor, OPG. Disruption of their balanced expression leads to bone loss, as demonstrated in experimental models of bone destructive diseases, including periodontitis.\[[@ref9]\] In our present study, we analyzed the levels of RANKL and OPG in GCF after placement of collagen membrane with simvastatin, in intrabony defects. Simvastatin-loaded collagen membrane expressed increased OPG levels and decreased RANKL levels, which could have a potential role in periodontal regeneration.

This was in accordance with the study done by Han *et al*.\[[@ref10]\] in which they demonstrated that simvastatin inhibited the activity of osteoclasts and stimulated new bone formation in rat periodontal tissues, which resulted in increase in OPG and a decrease in RANKL levels. In support with our study Ayukawa *et al*.\[[@ref11]\] also observed that when artificial bone defects treated with simvastatin showed decreased expression of RANKL levels with fewer osteoclasts.

Pagkalos *et al*.\[[@ref12]\] highlighted that only lipophilic statins (e.g., simvastatin) have these effects on bone, because their lipophilia allows them to cross the cell membrane by passive diffusion mechanisms. They also deliver benefits at the bone level through their anti-inflammatory action and through their angiogenic effect because they are able to stimulate the vascular endothelial growth factor. Ruan *et al*.\[[@ref13]\] reported that simvastatin reduced the expression of iNOS and increased BMP-2 and OPG levels in the periodontal tissue, which affects the bone resorption through the modulation of BMP-2 in osteoblasts. Furthermore, Mundy *et al*.\[[@ref14]\] demonstrated increased BMP-2 expression following treatment of murine (2T3) and human (MG63) cell lines with simvastatin. Collectively, all these findings strengthen our result that simvastatin is associated with increasing OPG concentrations and decreasing RANKL, which could have a protective effect against bone breakdown and periodontal attachment loss.

In conclusion, statins have a broad therapeutic effect beyond that of cardioprotection and potentially show great promise in regenerative therapies. Statins are able to achieve the goal of periodontal regeneration.
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